Before protein bars, smoothie bowls, and modern wellness trends, American kitchens and school cafeterias served simple comfort foods that defined a generation. If these dishes sound familiar, there’s ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...